Third-generation EGFR-TKIs are approved as the first-line treatment for patients with advanced EGFR-mutant NSCLC; however acquired resistance is also inevitable in such patients, and the options for posterior-line therapy remain limited (4–7). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.